MRTX - Mirati crashes after updating mid-stage data for KRAS inhibitor in lung cancer

Mirati Therapeutics (NASDAQ:MRTX) plunged 23% in the post-market Thursday after the clinical-stage oncology company shared trial data for its oral KRAS inhibitor, adagrasib, in lung cancer patients with KRASG12C mutation . The data were derived from the registration-enabling Phase 2 cohort of KRYSTAL-1 study that involved 116 patients with non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. The results as of Oct. 15, 2021, indicated that the experimental drug at 600 mg BID led to 43% of objective response rate (ORR) out of 112 patients who were evaluable for response. The data demonstrated a disease control rate (DCR) and median progression-free survival (PFS) at 80% and 8.5 months, respectively, with a median follow up was 12.9 months. As of Jan. 15, 2022, the median overall survival (OS), a key measure indicating an efficacy of a cancer drug, stood at 12.6 months. The safety profile of the

For further details see:

Mirati crashes after updating mid-stage data for KRAS inhibitor in lung cancer